Results of a study comparing weight loss success of a diet and physical activity intervention with self-directed weight loss among ALL survivors are presented at 2021 ASCO Annual Meeting.
Progression-free and overall survival were superior in patients who received immunotherapy and chemotherapy.
Patients who experienced immune-related adverse events had longer overall survival than those who did not in both the atezolizumab-containing and control arms.
First-line treatment with nivolumab in combination with ipilimumab and chemotherapy provided durable survival compared to chemotherapy alone in patients with NSCLC.
Results of a secondary analysis on oncology-patient communications regarding FS and PP concerns were presented at the 2021 ASCO Annual Meeting.
A symptom-adapted physical activity intervention helped older adults with AML to maintain their physical function while undergoing induction chemotherapy.
